7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies
Key Takeaways
- HCT survivors need lifelong, exposure- and age-adapted surveillance for subsequent malignancies; chronic oral/skin GVHD, radiation, immunosuppression, HPV and prior cytotoxic therapy refine risk.
- Endocrine follow-up addresses thyroid, gonadal/fertility, growth and adrenal effects using symptoms, treatment exposure and age; hormone therapy requires individualized contraindication and preference review.
- Cardiovascular follow-up uses blood pressure, lipids, glucose, lifestyle and exposure-based cardiac testing; targets follow current general and cardio-oncology guidance rather than one transplant-only number.
- Bone/joint care includes fracture risk and bone-density assessment plus prompt MRI when persistent weight-bearing joint pain raises concern for osteonecrosis despite normal radiographs.
- Eye, oral, dental, skin, sexual-health and rehabilitation review should be integrated into a written survivorship plan with named owners and intervals.
Late Effects: Endocrine, Cardiovascular, Bone Health and Subsequent Malignancies
Clinical principle: Long-term risk follows the patient's disease, age, conditioning and radiation fields/doses, prior chemotherapy, transplant type, GVHD, immunosuppression, infections, family history and health behaviors. Combine current general-population screening with HCT-specific exposure guidance and update the plan over time.
1. Subsequent Malignancies
Subsequent neoplasms include therapy-related MDS/AML, PTLD and solid cancers. Therapy-related myeloid disease is especially relevant after extensive prior chemotherapy and autologous HCT; unexplained persistent cytopenias require marrow and clonal evaluation rather than assuming late graft suppression. EBV/PTLD risk is highest in defined T-cell-depleted or heavily immunosuppressed settings and can occur earlier than most solid tumors.
Chronic oral GVHD and prolonged immunosuppression increase oral squamous-cell risk. Teach patients to report a nonhealing ulcer, induration, leukoplakia/erythroplakia, bleeding or new pain and provide at least annual oral/dental assessment, more often for active disease or lesions. Use regular skin self-examination, sun protection and clinician/dermatology examination based on skin GVHD, immunosuppressants and prior voriconazole/radiation exposure.
Continue age-appropriate colorectal, cervical, prostate and lung screening, adjusting for immune status and treatment exposure. For patients exposed to chest radiation or TBI at a young age, use the current radiation-survivorship breast-screening schedule—often annual mammography with MRI beginning at age 25 or eight years after exposure, whichever is later, and no later than age 40—after confirming dose and guideline. HPV vaccination and cervical/anogenital surveillance are individualized by age, immune status and current national guidance.
2. Endocrine and Reproductive Effects
Check thyroid function periodically, commonly at least annually after HCT and especially after TBI or neck radiation; evaluate symptoms or nodules promptly. Gonadal injury can cause infertility, ovarian insufficiency, low testosterone, sexual dysfunction and bone loss, but recovery varies by age, dose and regimen. Offer fertility preservation before gonadotoxic therapy when time and condition permit. After HCT, assess menstrual/sexual symptoms, fertility goals and age-appropriate gonadal hormones. Estrogen/progestin or testosterone therapy may benefit selected patients but requires contraindication, thrombosis, cancer, fertility and preference review with the appropriate specialist.
Prolonged corticosteroids can suppress the HPA axis. During taper or illness, evaluate fatigue, nausea, hypotension, hyponatremia or hypoglycemia and follow the prescribed sick-day/stress-dose plan. Morning cortisol and stimulation-test interpretation are assay- and context-dependent; no single study-guide cutoff replaces endocrinology or protocol guidance.
Pediatric survivors also require growth, pubertal, thyroid, bone and neurocognitive monitoring through development. Coordinate pediatric endocrinology from exposures and growth trajectory rather than ordering one universal bone-age interval.
3. Cardiovascular and Metabolic Health
Anthracyclines, chest/TBI radiation, endothelial injury, kidney disease, inactivity, corticosteroids and calcineurin/mTOR inhibitors can contribute to hypertension, dyslipidemia, diabetes, cardiomyopathy and vascular disease. Measure blood pressure and weight, screen glucose and lipids at guideline-appropriate intervals, promote tobacco avoidance, activity, nutrition and sleep, and manage risk using current primary-care/cardio-oncology targets. Echocardiography frequency follows cumulative anthracycline/radiation exposure, symptoms, pregnancy plans and prior dysfunction; it is not automatically every one to five years for everyone. New dyspnea, edema, chest pain, syncope or palpitations needs prompt evaluation.
4. Bone, Joint and Muscle Health
Corticosteroids, gonadal failure, inactivity, low weight and vitamin-D/calcium deficits raise fracture risk. Obtain bone-density testing from baseline risk and exposure—often around one year after HCT or earlier with substantial steroid risk—and repeat from results and ongoing therapy. Encourage weight-bearing/resistance activity when safe, fall prevention and adequate dietary calcium/vitamin D; supplements and antiresorptive drugs require renal, dental, fracture and laboratory review.
Osteonecrosis commonly affects femoral or humeral heads after corticosteroid exposure. Persistent deep groin/hip or shoulder pain, especially with weight bearing, warrants imaging even when plain radiographs are normal. MRI is the most sensitive test for early osteonecrosis. Protect the joint and involve orthopedics; management ranges from activity modification to joint-preserving procedures or arthroplasty based on stage.
5. Eyes and Other Organ Follow-up
TBI, corticosteroids and chronic GVHD can cause cataracts, dry eye and other ocular disease. Ask about glare, halos, visual loss, pain and photophobia and arrange ophthalmic assessment from exposure/symptoms, commonly at least yearly in high-risk survivors. Also review renal, pulmonary, hepatic, neurologic, dental, sexual, functional and psychosocial late effects.
6. Survivorship Plan
Record diagnosis and prior therapy, conditioning agents/doses, radiation fields/dose, graft/donor, major infections, GVHD organs and immunosuppression. For each surveillance item specify what is due, interval, responsible clinician, actionable threshold and transplant-team contact. Reconcile this plan with current primary-care, infectious-disease and cancer-screening guidance at least annually and after a new exposure or complication.
7. Transfusional Iron Overload After Transfusion Independence
Patients accumulate a substantial iron burden across pre-transplant therapy and the transplant itself, and because there is no physiologic route for excreting excess iron, that burden persists long after transfusions stop. Deposition in liver, heart, and endocrine tissue contributes to fibrosis, cardiomyopathy, diabetes, and hypogonadism, and it compounds late effects the survivor is already at risk for.
Assessment is deliberately not ferritin alone. Ferritin is an acute-phase reactant that rises with inflammation, infection, and GVHD, so a high value in an unwell patient may reflect none of it. Programs pair ferritin trends with transfusion history and, when quantification matters, hepatic MRI using R2* or T2* techniques to measure liver iron concentration directly.
Management waits until the patient is transfusion-independent and stable. Therapeutic phlebotomy is generally preferred when the hemoglobin supports it, because it is inexpensive, well tolerated, and avoids drug toxicity. Iron chelation is reserved for patients who cannot tolerate phlebotomy, remain transfusion-dependent, or carry a burden that requires faster reduction, and it brings its own renal, hepatic, ocular, and auditory monitoring obligations. Both pathways are long-term commitments that belong in the survivorship plan with a named owner.
A survivor with prior TBI and chronic oral GVHD returns six years after HCT. Which surveillance principle is most important?
A 34-year-old patient who received high-dose corticosteroids for 9 months to treat chronic GVHD reports progressive, aching right groin and anterior hip pain that worsens with weight-bearing. Plain radiographs of the right pelvis and hip show no bony abnormalities. What is the most appropriate next clinical step?
A young survivor has ovarian insufficiency symptoms and laboratory findings after TBI. What is the best management principle?